Antifibrotic Therapy

Impact of Antifibrotic Dose Modifications on Idiopathic Pulmonary Fibrosis Outcomes: Insights from Real-World Data

By MedXY 10/09/2026

This study investigates how dose reductions and discontinuations of antifibrotic therapies influence disease progression in idiopathic pulmonary fibrosis (IPF), revealing significant challenges in drug tolerability and the need for improved treatments.

news Otorhinolaryngology

Comparative Evaluation of Topical versus Systemic Pirfenidone for Prevention of Glottic Stenosis in a Rat Model

By MedXY 09/17/2026

This study investigates the efficacy of topical and systemic pirfenidone in reducing glottic stenosis induced by bleomycin in rats, demonstrating both routes reduce macroscopic stenosis, with systemic administration showing significant antifibrotic effects.

news Oncology Radiology Respiratory

Pirfenidone plus Steroids Improves Gas Transfer in Grade 2–3 Radiation‑Induced Lung Injury: Phase 2 Multicentre Randomised Trial

By MedXY 11/12/2025

A multicentre phase 2 randomised trial found pirfenidone added to standard glucocorticoids improved DLCO% at 24 weeks versus steroids alone in grade 2–3 radiation‑induced lung injury, with manageable safety and no treatment‑related deaths.

Clinical Updates Respiratory Specialties

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial

By MedXY 09/17/2025

The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.